Chugai Of Japan Ties With U.S. Firm To Develop Key Hepatitis Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical has signed an agreement with Romark Laboratories of the United States to develop a nitazoxanide drug to treat hepatitis C. The drug is in the relatively new class of thiazolide antiviral drugs invented by the chairman of Romark. The firm, already is developing thiazolides for other treatments, including hepatitis B. Few details of the tie-up were detailed beyond payment schedules. (Click here for more
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.